Glofitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies: Results From a Pivotal Phase II Expansion Study

被引：0
|
作者：
Dickinson, Michael [1 ,2 ]
Carlo-Stella, Carmelo [3 ,4 ]
Morschhauser, Franck [5 ,6 ]
Bachy, Emmanuel [7 ]
Corradini, Paolo [8 ,9 ]
Iacoboni, Gloria [10 ]
Khan, Cyrus [11 ]
Wrobel, Thomasz [12 ]
Offner, Fritz [13 ]
Trneny, Marek [14 ]
Wu, Shang-Ju [15 ]
Cartron, Guillaume [16 ]
Hertzberg, Mark [17 ,18 ]
Sureda, Anna [19 ]
Perez-Callejo, David [20 ]
Lundberg, Linda [20 ]
Relf, James [21 ]
Clark, Emma [21 ]
Humphrey, Kathryn [21 ]
Hutchings, Martin [22 ]
机构：
[1] Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Univ Melbourne, Melbourne, Vic, Australia
[3] Humanitas Univ, Milan, Italy
[4] IRCCS Humanitas Res Hosp, Milan, Italy
[5] Hop Claude Huriez, Lille, France
[6] CHU Lille, Lille, France
[7] Ctr Hosp Lyon Sud, Lyon, France
[8] Univ Milan, Milan, Italy
[9] IRCSS Ist Nazl Tumori, Fdn Ist Ricovero & Cura Carattere Sci, Milan, Italy
[10] Vall dHebron Univ Hosp, Barcelona, Spain
[11] Allegheny Hlth Network, Pittsburgh, PA USA
[12] Uniwersytet Med Wroclawiu, Wroclaw, Poland
[13] Univ Ziekenhuis Gent, Ghent, Belgium
[14] Charles Univ Hosp, Prague, Czech Republic
[15] Natl Taiwan Univ Hosp, Taipei, Taiwan
[16] CHU Montpellier, Montpellier, France
[17] Prince Wales Hosp, Sydney, NSW, Australia
[18] Univ New South Wales, Sydney, NSW, Australia
[19] Inst Catala Oncol Hosp, Barcelona, Spain
[20] F Hoffmann La Roche Ltd, Basel, Switzerland
[21] Roche Prod Ltd, Welwyn Garden City, Herts, England
[22] Rigshosp, Copenhagen, Denmark
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
ABCL; glofitamab; diffuse large B-cell lymphoma; bispecific antibody; relapsed/refractory; phase II;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ABCL-478
引用
收藏
页码：S435 / S435
页数：1
相关论文
共 50 条
  • [21] Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Friedberg, Jonathan W.
    HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM, 2011, : 498 - 505
  • [22] A Phase I Study of Copanlisib and Venetoclax in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Crombie, Jennifer L.
    Kim, Austin I.
    Bartlett, Nancy L.
    Redd, Robert A.
    Patterson, Victoria
    Carey, Celeste
    Balasubramanian, Sobana
    Odejide, Oreofe O.
    Merryman, Reid W.
    LaCasce, Ann
    Jacobson, Caron A.
    Jacobsen, Eric
    Parry, Erin M.
    Fisher, David C.
    Herrera, Alex F.
    Davids, Matthew S.
    Shipp, Margaret A.
    Armand, Philippe
    Shouse, Geoffrey P.
    BLOOD, 2023, 142
  • [23] Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma: Real World Data
    Ferhanoglu, Burhan
    Gulbas, Zafer
    Uzay, Ant
    Ozcan, Muhit
    Ozkalemkas, Fahir
    Dal, Mehmet Sinan
    Kalyon, Hakan
    Akay, Olga Meltem
    Deveci, Burak
    Bekoz, Huseyin
    Sevindik, Omur Gokmen
    Toptas, Tayfur
    Yilmaz, Asu Fergun
    Koyun, Derya
    Alkis, Nihan
    Atesoglu, Elif Birtas
    BLOOD, 2022, 140 : 6704 - 6705
  • [24] New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma
    Moore, Donald C.
    Peery, Matthew R.
    Tobon, Katherine A.
    Raheem, Farah
    Hwang, Grace S.
    Alhennawi, Lin
    Hughes, Mitchell E.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (08) : 1848 - 1858
  • [25] Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies
    Sawalha, Yazeed
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (12):
  • [26] Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
    Ren, Liangliang
    Li, Ling
    Zhang, Lei
    Li, Xin
    Fu, Xiaorui
    Wang, Xinhua
    Wu, Jingjing
    Sun, Zhenchang
    Feng, Xiaoyan
    Chang, Yu
    Zhou, Zhiyuan
    Nan, Feifei
    Yan, Jiaqin
    Kong, Fei
    Zhang, Mingzhi
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2022, 38 (01) : 42 - 50
  • [27] Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study
    Palomba, M. Lia
    Till, Brian G.
    Park, Steven I.
    Morschhauser, Franck
    Cartron, Guillaume
    Marks, Reinhard
    Shivhare, Mahesh
    Hong, Wan-Jen
    Raval, Aparna
    Chang, Alice C.
    Penuel, Elicia
    Popplewell, Leslie L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : E443 - E451
  • [28] Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
    Liangliang Ren
    Ling Li
    Lei Zhang
    Xin Li
    Xiaorui Fu
    Xinhua Wang
    Jingjing Wu
    Zhenchang Sun
    Xiaoyan Feng
    Yu Chang
    Zhiyuan Zhou
    Feifei Nan
    Jiaqin Yan
    Fei Kong
    Mingzhi Zhang
    Indian Journal of Hematology and Blood Transfusion, 2022, 38 : 42 - 50
  • [29] Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase II Study
    Bennani, N. Nora
    Atherton, Pamela
    Steinert, Kimberly O.
    Rimsza, Lisa M.
    Tun, Aung M.
    Hoffmann, Marc S.
    Narkhede, Mayur S.
    Vaidya, Rakhee
    Said, Rabih
    Shapiro, Geoffrey I.
    Costello, Brian A.
    Ansell, Stephen M.
    Nowakowski, Grzegorz S.
    BLOOD, 2023, 142
  • [30] A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Kambhampati, Swetha
    Kallam, Avyakta
    Borogovac, Azra
    Chen, Lu
    Puverel, Sandrine
    Johnson, Jennifer
    Melgar, Ivana
    Baird, John H.
    Danilov, Alexey
    Godfrey, James
    Khan, Niloufer
    Mei, Matthew
    Phillips, Tycel J. J.
    Siddiqi, Tanya
    Shouse, Geoffrey
    Zain, Jasmine
    Kwak, Larry W.
    Rosen, Steven T.
    Forman, Stephen J.
    Song, Joo Y.
    Herrera, Alex F.
    Budde, Elizabeth
    BLOOD, 2024, 144 : 17421 - 17422
12345